Compare ANTA & PLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANTA | PLYX |
|---|---|---|
| Founded | 2022 | 2014 |
| Country | Singapore | United States |
| Employees | 113 | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.7M | 271.8M |
| IPO Year | N/A | N/A |
| Metric | ANTA | PLYX |
|---|---|---|
| Price | $8.60 | $5.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $16.17 | $10.00 |
| AVG Volume (30 Days) | 8.1K | ★ 117.1K |
| Earning Date | 06-16-2026 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $21.95 | N/A |
| Revenue Next Year | $30.46 | N/A |
| P/E Ratio | $19.77 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.25 | $2.20 |
| 52 Week High | $15.65 | $9.18 |
| Indicator | ANTA | PLYX |
|---|---|---|
| Relative Strength Index (RSI) | 49.52 | 45.17 |
| Support Level | $8.54 | $4.86 |
| Resistance Level | $10.12 | $5.68 |
| Average True Range (ATR) | 0.60 | 0.59 |
| MACD | -0.06 | -0.11 |
| Stochastic Oscillator | 27.31 | 15.17 |
Antalpha Platform Holding Co provides financing, technology and risk management solutions to the digital asset industry. It is a provider of supply chain financing solutions to institutional and corporate participants in the Bitcoin mining industry, offering loans secured by Bitcoin and Bitcoin mining machines. It has developed a technology platform, Antalpha Prime, which enables customers to apply for and manage their digital asset loans while allowing to closely monitor collateral positions.
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.